Zoloft 50 mg Norwe - Kinorwe - Statens legemiddelverk

zoloft 50 mg

upjohn eesv - sertralinhydroklorid - tablett, filmdrasjert - 50 mg

Zoloft 25 mg Norwe - Kinorwe - Statens legemiddelverk

zoloft 25 mg

upjohn eesv - sertralinhydroklorid - tablett, filmdrasjert - 25 mg

Zoloft 100 mg Norwe - Kinorwe - Statens legemiddelverk

zoloft 100 mg

upjohn eesv - sertralinhydroklorid - tablett, filmdrasjert - 100 mg

Ozalin 2 mg/ ml Norwe - Kinorwe - Statens legemiddelverk

ozalin 2 mg/ ml

primex pharmaceuticals oy - midazolam - mikstur, oppløsning i endosebeholder - 2 mg/ ml

Sertraline Accord 50 mg Norwe - Kinorwe - Statens legemiddelverk

sertraline accord 50 mg

accord healthcare b.v. - sertralinhydroklorid - tablett, filmdrasjert - 50 mg

Sertraline Accord 100 mg Norwe - Kinorwe - Statens legemiddelverk

sertraline accord 100 mg

accord healthcare b.v. - sertralinhydroklorid - tablett, filmdrasjert - 100 mg

Copiktra Umoja wa Ulaya - Kinorwe - EMA (European Medicines Agency)

copiktra

secura bio limited - duvelisib - leukemia, lymphocytic, chronic, b-cell; lymphoma, follicular - antineoplastiske midler - copiktra monotherapy is indicated for the treatment of adult patients with: relapsed or refractory chronic lymphocytic leukaemia (cll) after at least two prior therapies.  follicular lymphoma (fl) that is refractory to at least two prior  systemic therapies.

Utrogestan 300 mg Norwe - Kinorwe - Statens legemiddelverk

utrogestan 300 mg

besins healthcare ireland limited (1) - progesteron - vaginalkapsel, myk - 300 mg

Brukinsa Umoja wa Ulaya - Kinorwe - EMA (European Medicines Agency)

brukinsa

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastiske midler - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).